A pre-clinical study published in The Lancet on June 25 found that mixing AstraZeneca with a second dose of Pfizer provides "robust" protection from severe COVID-19. The pre-clinical study was ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...
Zacks Investment Research on MSN
AstraZeneca's Ultomiris meets goal in rare kidney disease study
AstraZeneca AZN announced positive results from an interim analysis of the ongoing late-stage I CAN study, which evaluated ...
AstraZeneca is forecast to report core earnings per share--its preferred metric, which strips out exceptional and other one-off items--of $2.54, according ...
"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...
People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results